Efficacy and safety of raltegravir plus lamivudine maintenance therapy.

Beatriz BorjabadAlexy InciarteIvan ChiviteAna Gonzalez-CordonMar MosqueraCarmen HurtadoCristina RoviraTania GonzalezAbiu SempereBerta TorresJulia CalvoLorena De La MoraMaria Martinez-RebollarMontserrat LagunoAlberto FoncillasJuan AmbrosioniJordi BlanchAna RodriguezEstela SolbesRoger LlobetLeire BerrocalJosep MallolasJose M MiroJose AlcamiJose L BlancoSonsoles Sanchez-PalominoElisa De LazzariEsteban Martinez

Published in: The Journal of antimicrobial chemotherapy (2023)

Switching to raltegravir and lamivudine in PWH with virological suppression maintains efficacy and is well tolerated. This maintenance regimen might be a cost-effective option for PWH at risk of drug-drug interactions or needing to avoid specific toxicities of certain antiretroviral drugs or their negative impact on comorbidities.

Keyphrases

hiv infected patients
antiretroviral therapy
hiv infected
human immunodeficiency virus
hiv aids
drug induced
emergency department